CAPharmd

CAPharmd
Send Message
View as an RSS Feed
  • Relypsa: A Factual Approach To Analyzing The Veltassa Bear Thesis  [View article]
    White coat mafia: appreciate in providing a very well written article with facts. I posted my one to one interviews with 2 nephrologists on twtr (you are aware of that interview analysis too). I interviewed 2 local nephrologists at the hospital I work ( in ER). The end point of that interview was that both docs are very excited to prescribe veltassa to their patients on chronic management of hyperkalemia. One of the docs stated about his concerns in increase in potassium levels when treating pts with RAASi therapies even though these meds are highly recommended for this population especially with diabetics (kidney protection). Furthermore, he stated that with veltassa approval, their concerns about hyperkalemia will diminish to a large extent as veltassa will help reducing the incidence of hyperkalemia. Both docs looking forward to prescribing veltasssa.
    Thank you for your article.
    Dec 1, 2015. 10:20 PM | 10 Likes Like |Link to Comment
  • ZS-9 Label May Restrict Use In Patients With Renal Disease, Heart Failure, And Hypertension  [View article]
    Gary, Thanks for updating that information from your wife's perspective. That's the discussion we were having past week that rlyp will be prescribed and when zsph hits the market both will have their own share of market depending on individual pt scenario. Again, that DDI story will change once we see the data early january. thanks
    Nov 17, 2015. 02:16 PM | 1 Like Like |Link to Comment
  • A Deep Dive Into What ZS Pharma's ZS005 Interim Safety Signals Might Mean For Relypsa's Veltassa  [View article]
    relypsa will have an uphill struggle: great point doc. Can you elaborate on it. You are comparing with zsph that's month's behind rlyp not even approved yet and study hasn't finished. Moreover, study might get pushed a bit and then come back and make your claims. You telling people here that good physicians will wait for zsph approval and not going to prescribe rlyp drug. insane thoughts. A good physician treats pts with available drugs on the market, and changes to other meds if better in terms of efficacy and tolerability.
    Nov 17, 2015. 02:06 PM | Likes Like |Link to Comment
  • A Deep Dive Into What ZS Pharma's ZS005 Interim Safety Signals Might Mean For Relypsa's Veltassa  [View article]
    you can't compare with mnkd. tons of meds to treat diabetes but none for hyper kalemia. Moreover. inhaler wasn't accepted by medical community
    Nov 17, 2015. 01:16 AM | 1 Like Like |Link to Comment
  • A Deep Dive Into What ZS Pharma's ZS005 Interim Safety Signals Might Mean For Relypsa's Veltassa  [View article]
    I guess one odd so called doc will prescribe zsph. remember not every physician is smart. I worked with all kinds of physicians in ER and one can't even tell the difference between humalog and lantus. Smart physicians will prescribe zsph or rlyp drug based on different pt scenarios not just give damn zsph to everyone and overload with sodium. I guess this physician is just blinded by zsph and nothing else. both are good drugs but there are issues with zsph and will become issues with fda.
    Nov 17, 2015. 01:15 AM | 7 Likes Like |Link to Comment
  • A Deep Dive Into What ZS Pharma's ZS005 Interim Safety Signals Might Mean For Relypsa's Veltassa  [View article]
    Well, wait for zsph trial to finish, then approval. zsph is not approved buddy.
    Nov 17, 2015. 01:09 AM | Likes Like |Link to Comment
  • ZS-9 Label May Restrict Use In Patients With Renal Disease, Heart Failure, And Hypertension  [View article]
    Good article. Overall market discounted zsph latest data in terms of adverse reactions and focused primarily on 6 hour rlyp boxed warning. This is typical Wall Street where one analyst with an agenda ignored completely the edema and HTN issues of zsph and on the other hand deliberately missed focus on clear safety profile of rlyp in terms of no edema and HTN. Clinicians will see the clear difference between rlyp and zsph and should prefer rlyp because why giving high sodium content of zsph drug to pts already on salt restrictions, edema and HTN issues. great article
    Nov 13, 2015. 02:31 PM | 7 Likes Like |Link to Comment
  • ZS Pharma Vs. Relypsa: A Comparison Of 2 Drugs' Side Effect Profiles  [View article]
    rlyp is undervalued compared to zsph. people are debating how good zsph drugs is. they need to consider one fact first : its not approved yet, months behind rlyp. Trial hasn't finished and who knows if adverse events gets worse once study comes to completion. Moreover, with edema and HTN issues fda will not make an easy pass for zsph.
    Nov 11, 2015. 05:56 PM | 5 Likes Like |Link to Comment
  • ZS Pharma Vs. Relypsa: A Comparison Of 2 Drugs' Side Effect Profiles  [View article]
    wallstpriate: thanks buddy for nicely bringing these points. I deal with these drug interactions all day long going through tons of medications that pts on especially in kidney failure. When these pts are admitted from ER to a critical care area, new medications are added that have interactions with their home meds. Its all about drug management as long as no severe interactions exist, then the therapy has to be changed.
    Nov 11, 2015. 05:54 PM | 3 Likes Like |Link to Comment
  • ZS Pharma Vs. Relypsa: A Comparison Of 2 Drugs' Side Effect Profiles  [View article]
    Wow, so you think md's going to wait for 6-7 months for zsph drug. Really?
    This is a big market, pts need immediate therapy. Docs not to going to wait for zsph drug. There priority is patients not when second drug going to be available. Moreover, you keep on bringing your wife discussion here. There is a big difference between acute and chronic treatment buddy. 90% market is chronic not acute. Go ahead use zsph for acute tx then what? Give these pts with renal failure and heart issue zsph to maintain normal potassium. Good luck buddy with that thesis. Stop making zsph a wonder drug and its not. Personally, ER is my clinical expertise where I see these pts regularly and in ER the primary focus is normalizing potassium levels acutely and then once pts going to be discharged, the primary focus will shift to keeping that potassium level under control to reduce hospitalizations. I really love your hypothesis that docs going to wait for 6-8 months for zsph approval and in the meantime they will be avoiding using a safe drug. Moreover, about your drug interaction issues, this is absolutely a blown up issue by MS analyst (one pumping zsph). rlyp is once a day drug. These interactions are minimal and could be easily managed.
    Nov 11, 2015. 05:50 PM | 3 Likes Like |Link to Comment
  • ZS Pharma Vs. Relypsa: A Comparison Of 2 Drugs' Side Effect Profiles  [View article]
    Gary: I directly work with pts in ER all day long with these issues. One thing you are absolutely wrong is the market penetration. 90% market is outpatient setting to prevent hyperkalemia not in patient like ER (my setting). We treat pts high potassium levels and once pts stabilize they are discharged. This is where rlyp usage comes for prevention. zsph should not be a drug of choice for pts with edema and HTN problems.
    Nov 11, 2015. 12:50 PM | 6 Likes Like |Link to Comment
  • ZS Pharma Vs. Relypsa: A Comparison Of 2 Drugs' Side Effect Profiles  [View article]
    John: Only 61 pts out of 683 reached 52 wks. Edema issue %age will be higher once all pts reached 52 wks.
    Nov 10, 2015. 09:48 PM | 1 Like Like |Link to Comment
  • ZS Pharma Vs. Relypsa: A Comparison Of 2 Drugs' Side Effect Profiles  [View article]
    Dr Rodney,
    My primary practice in ER: On daily basis, we treat pts in ER with SPS, albuterol, sod. bicarb, insulin to lower potassium acutely. Most of these pts already on fluid restriction, salt restrictions presenting with fluids in lower extremities and EF < 30% (heart failure). In regards to zsph: only 61 pts out of 683 reached 52 wks. 7.7% pts develop peripheral edema and 4.2% required tx with diuretics. 7% developed HTN. Potassium is exchanged with sodium (zsph) whereas potassium is exchanged with calcium (rlyp) but only 5% of calcium is absorbed since vitamin D is required for absorption of calcium in gut, but ingested sodium in case of zsph gets absorbed. Overall, rlyp is a first approved drug to market with launch early jan 2016 whereas zsph is months behind it. On outpatient basis, rlyp will be the drug of choice given once a day with no edema and htn issues.
    Nov 10, 2015. 09:44 PM | 5 Likes Like |Link to Comment
  • ZS Pharma Vs. Relypsa: A Comparison Of 2 Drugs' Side Effect Profiles  [View article]
    SAY WHAT: what's your background to make these comments. Support your thesis. If fda does approve zsph, it will put severe black box warning and the label will be restricted but the question if fda decides to approve.
    Nov 10, 2015. 05:42 PM | Likes Like |Link to Comment
  • ZS Pharma Vs. Relypsa: A Comparison Of 2 Drugs' Side Effect Profiles  [View article]
    He has no counter arguments just replying bs to all comments. Bring your scientific knowledge out buddy. rlyp is the winner in chronic tx of hyperkalemia in outpatient setting
    Nov 10, 2015. 05:38 PM | 6 Likes Like |Link to Comment
COMMENTS STATS
390 Comments
463 Likes